Crohn’s Disease: Treatment

Crohn’s Disease: Treatment

  • December 2017 •
  • 52 pages •
  • Report ID: 5336394 •
  • Format: PDF
Datamonitor Healthcare surveyed 240 gastroenterologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain insight into Crohn’s disease diagnosis, patient segmentation, and current and future prescribing patterns.

This module is accompanied by a datapack showing treatment trees, which provide an approximation of the potential patient populations at each step in the treatment algorithm and indicate estimated patient numbers; they should not be interpreted as showing exact patient numbers.

Datamonitor Healthcare’s 2016 survey reveals that biologic usage in the US, Japan, and five major EU markets increases as Crohn’s disease patients progress through lines of therapy. This is in line with available clinical guidelines. Infliximab – the reference brand and its biosimilar versions – remains the most frequently prescribed biologic in the Crohn’s disease market.

The use of integrin receptor inhibitors remains low. US gastroenterologists favor Entyvio over Tysabri due to its superior safety profile.

The development of therapies that achieve long-term remission without the need for immunosuppression remains the most prominent unmet need in Crohn’s disease.

Datamonitor Healthcare expects the use of biosimilars to increase in all patient subpopulations in the near future, driven by lower costs and increasing availability of long-term safety data.

Datamonitor Healthcare conducted a survey of 240 gastroenterologists in the US, Japan, and five major EU markets on their Crohn’s disease treatment choices and prescribing habits.